273 related articles for article (PubMed ID: 12722397)
1. [Intraperitoneal hyperthermic perfusion chemotherapy in recurrent ovarian cancer].
Wydra D; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1044-7. PubMed ID: 12722397
[TBL] [Abstract][Full Text] [Related]
2. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.
Helm CW
Surg Oncol Clin N Am; 2012 Oct; 21(4):645-63. PubMed ID: 23021722
[TBL] [Abstract][Full Text] [Related]
3. Combination of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with intraperitoneal chemotherapy as a treatment modality for persistent ovarian cancer.
Wydra D; Sawicki S; Ciach K; Marciniak A; Emerich J
Eur J Gynaecol Oncol; 2007; 28(2):128-30. PubMed ID: 17479675
[TBL] [Abstract][Full Text] [Related]
4. Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.
Cavaliere F; Di Filippo F; Botti C; Cosimelli M; Giannarelli D; Aloe L; Arcuri E; Aromatario C; Consolo S; Callopoli A; Laurenzi L; Tedesco M; Di Angelo P; Giunta S; Cavaliere R
Eur J Surg Oncol; 2000 Aug; 26(5):486-91. PubMed ID: 11016471
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer.
Hager ED; Dziambor H; Höhmann D; Mühe N; Strama H
Int J Gynecol Cancer; 2001; 11 Suppl 1():57-63. PubMed ID: 11489005
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
7. [Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].
Bespalov VG; Kireeva GS; Belyaeva OA; Senchik KY; Stukov AN; Gafton GI; Soloviev LA; Vasilchenko MV; Guseinov KD; Alexeev VV; Belyaev AM
Vopr Onkol; 2015; 61(4):647-52. PubMed ID: 26571838
[TBL] [Abstract][Full Text] [Related]
8. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
[TBL] [Abstract][Full Text] [Related]
9. Cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis of ovarian cancer.
Lee JM
Cancer Treat Res; 2007; 134():375-85. PubMed ID: 17633067
[No Abstract] [Full Text] [Related]
10. Simulation of Chemoperfusion Treatment for Abdominal Carcinomatosis.
Bespalov VG; Belyaeva OA; Kireeva GS; Senchik KY; Stukov AN; Belyaev AM
Bull Exp Biol Med; 2015 May; 159(1):81-4. PubMed ID: 26033596
[TBL] [Abstract][Full Text] [Related]
11. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal hyperthermic chemotherapy in ovarian cancer.
Gori J; Castaño R; Toziano M; Häbich D; Staringer J; De Quirós DG; Felci N
Int J Gynecol Cancer; 2005; 15(2):233-9. PubMed ID: 15823105
[TBL] [Abstract][Full Text] [Related]
13. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
[TBL] [Abstract][Full Text] [Related]
14. The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
Cavaliere F; Di Filippo F; Cosimelli M; Aloe L; Arcuri E; Anzà M; Callopoli A; Di Lauro L; Morace E; Botti C; Natoli S; Tedesco M; Giunta S; Cavaliere R
J Exp Clin Cancer Res; 1999 Jun; 18(2):151-8. PubMed ID: 10464701
[TBL] [Abstract][Full Text] [Related]
15. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
Cascales Campos P; Gil J; Parrilla P
Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
[TBL] [Abstract][Full Text] [Related]
16. [Anaesthesiologic problems about hyperthermic intraoperative intraperitoneal chemotherapy].
Izzo L; Pierannunzi F; Vari A; Riccardi S; Tarquini S; Fermariello A; Di Giorgio A; Casullo A; Caputo M; Costi U; Al Radhi H; Kharrub Z; Gazzanelli S
G Chir; 2004 Oct; 25(10):361-4. PubMed ID: 15756960
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.
Cattel L; De Simone M; Passera R; Verlengo MC; Delprino L
Anticancer Res; 2004; 24(3b):2041-5. PubMed ID: 15274398
[TBL] [Abstract][Full Text] [Related]
18. Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery.
Kanakoudis F; Petrou A; Michaloudis D; Chortaria G; Konstantinidou A
Anaesthesia; 1996 Nov; 51(11):1033-6. PubMed ID: 8943594
[TBL] [Abstract][Full Text] [Related]
19. [Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].
Ferron G; Martinez A; Mery E; Querleu D; Thomas F; Chatelut E; Gladieff L
Bull Cancer; 2009 Dec; 96(12):1243-52. PubMed ID: 19948452
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
